会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Formulations
    • 配方
    • US08420859B2
    • 2013-04-16
    • US12293894
    • 2007-03-21
    • Gordon BellIan David Tovey
    • Gordon BellIan David Tovey
    • C07C235/06C07C235/14A01N25/32
    • C07C235/06A01N25/32A01N43/653A61K8/42A61K31/16A61K2800/75A61Q5/02A61Q19/10C07C235/08C07C235/16C07D295/13C07D295/185A01N37/36A01N2300/00
    • This invention relates to the use of lactamide compounds of formula (I): CH3CH(OH)C(═O)NR1R2, where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl, in formulations to reduce the toxicity associated with other formulation components; to the use of certain lactamide compounds as solvents, especially in formulations, particularly in agrochemical formulations and in environmentally friendly formulations; to novel lactamide compounds; and to processes for preparing lactamide compounds.
    • 本发明涉及式(I)的乳酰胺化合物:CH 3 CH(OH)C(= O)NR 1 R 2,其中R 1和R 2各自独立地为氢; 或C 1-6烷基,C 2-6烯基或C 3-6环烷基,其各自任选被至多三个独立地选自苯基,羟基,C 1-5烷氧基,吗啉基和NR 3 R 4的取代基取代,其中R 3和R 4各自独立地为C 1 -3烷基; 或任选被至多三个独立地选自C 1-3烷基的取代基取代的苯基; 或R 1和R 2与它们所连接的氮原子一起形成吗啉基,吡咯烷基,哌啶基或氮杂环庚烷环,其各自任选被至多三个独立地选自C 1-3烷基的取代基取代,以减少毒性 与其他制剂成分有关; 使用某些乳酰胺化合物作为溶剂,特别是在制剂中,特别是在农药制剂和环境友好型制剂中; 新型乳酰胺化合物; 以及制备酰胺化合物的方法。
    • 2. 发明申请
    • FORUMLATIONS
    • 论证
    • US20090227453A1
    • 2009-09-10
    • US12293894
    • 2007-03-21
    • Gordon Alastair BellIan David Tovey
    • Gordon Alastair BellIan David Tovey
    • A01N25/32C07C235/02C07C231/02
    • C07C235/06A01N25/32A01N43/653A61K8/42A61K31/16A61K2800/75A61Q5/02A61Q19/10C07C235/08C07C235/16C07D295/13C07D295/185A01N37/36A01N2300/00
    • This invention relates to the use of lactamide compounds of formula (I): CH3CH(OH)C(═O)NR1R2, where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl, in formulations to reduce the toxicity associated with other formulation components; to the use of certain lactamide compounds as solvents, especially in formulations, particularly in agrochemical formulations and in environmentally friendly formulations; to novel lactamide compounds; and to processes for preparing lactamide compounds.
    • 本发明涉及式(I)的乳酰胺化合物:CH 3 CH(OH)C(-O)NR 1 R 2,其中R 1和R 2各自独立地为氢; 或C 1-6烷基,C 2-6烯基或C 3-6环烷基,其各自任选被至多三个独立地选自苯基,羟基,C 1-5烷氧基,吗啉基和NR 3 R 4的取代基取代,其中R 3和R 4各自独立地为C 1 -3烷基; 或任选被至多三个独立地选自C 1-3烷基的取代基取代的苯基; 或R 1和R 2与它们所连接的氮原子一起形成吗啉基,吡咯烷基,哌啶基或氮杂环庚烷环,其各自任选被至多三个独立地选自C 1-3烷基的取代基取代,以减少毒性 与其他制剂成分有关; 使用某些乳酰胺化合物作为溶剂,特别是在制剂中,特别是在农药制剂和环境友好型制剂中; 新型乳酰胺化合物; 以及制备酰胺化合物的方法。
    • 7. 发明申请
    • ORGANIC COMPOUNDS
    • 有机化合物
    • US20110230437A1
    • 2011-09-22
    • US12674741
    • 2008-08-12
    • Gordon Alastair BellClair Louise HarrisIan David Tovey
    • Gordon Alastair BellClair Louise HarrisIan David Tovey
    • A01N43/90A01N37/36A01N37/18A01N43/84A01N43/36A01N43/40A01N43/46
    • A01N25/02A01N37/36A01N37/42A01N43/90A01N2300/00
    • A composition comprising a compound of formula I CH3CH(OH)CC═O)NR1R2 (I) where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl; and at least one agrochemical selected from Othe group consisting of Tri nexepac ethyl, Mandipropamid, Abamcctin and Emamectin, with the proviso that the agrochemical is not abamectin or emamectin when the solvent is N-(B-hydroxyethyl)-lactamide. Such compositions may be, or may be comprised by, emulsion concentrates.
    • 包含式I的化合物CH 3 CH(OH)C C = O)NR 1 R 2(I)的组合物,其中R 1和R 2各自独立地为氢; 或C 1-6烷基,C 2-6烯基或C 3-6环烷基,其各自任选被至多三个独立地选自苯基,羟基,C 1-5烷氧基,吗啉基和NR 3 R 4的取代基取代,其中R 3和R 4各自独立地为C 1 -3烷基; 或任选被至多三个独立地选自C 1-3烷基的取代基取代的苯基; 或R 1和R 2与它们所连接的氮原子一起形成吗啉基,吡咯烷基,哌啶基或氮杂环庚烷环,其各自任选被至多三个独立地选自C 1-3烷基的取代基取代; 和至少一种选自三奈克乙基,Mandipropamid,Abamcctin和Emamectin的组合物,条件是当溶剂为N-(B-羟乙基) - 乳酰胺时,农药不是阿维菌素或阿维菌素。 这样的组合物可以是或可以由乳液浓缩物组成。